Inclusion Criteria:

        Patient -

          1. Is able to understand and voluntarily sign a written informed consent and is willing
             and able to comply with the protocol requirements including scheduled visits,
             treatment plan, laboratory tests and other study procedures

          2. Is aged ≥ 18 years

          3. Has documented diagnosis of symptomatic primary MF, PPV-MF or PET-MF as defined by the
             World Health Organization classification

          4. Is ineligible or unwilling to undergo stem cell transplantation at time of study entry

          5. Has laboratory function within specified parameters per local laboratory (may be
             repeated):

               -  Absolute neutrophil count (ANC) ≥ 100/mL; platelets ≥ 20,000/mL

               -  Transaminases (AST/ALT) and alkaline phosphatase ≤ 3 (≤ 10 X the upper limit of
                  normal (ULN) if considered to be MF-related) x ULN; bilirubin ≤ 1.5 x ULN (unless
                  patient has Gilbert's Syndrome)

               -  Serum amylase and lipase ≤ 1.5 x ULN

          6. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG) PS
             0-2

          7. Has received the final dose of any of the following treatments/procedures with the
             specified minimum intervals before first dose of 9-ING-41 (unless in the opinion of
             the investigator and the study medical coordinator the treatments/procedures will not
             compromise patient safety or interfere with study conduct:

               -  Chemotherapy, immunotherapy, or systemic radiation therapy - 14 days maximum, or
                  ≥ 5 half-lives (whichever is shorter)

               -  Surgery with general anesthesia - 7 days

          8. Patients who are to receive 9-ING-41 plus Ruxolitinib must have attempted ≥12 weeks of
             Ruxolitinib therapy and required dose reductions/interruptions and/or had an
             inadequate response

          9. Women of childbearing potential must have a negative baseline blood or urine pregnancy
             test within 72 hours of first study therapy. Women may be neither breastfeeding nor
             intending to become pregnant during study participation and must agree to use
             effective contraceptive methods (hormonal or barrier method of birth control, or true
             abstinence) for the duration of study participation and in the following 100 days
             after discontinuation of study treatment

         10. Male patients with partners of childbearing potential must take appropriate
             precautions to avoid fathering a child from screening until 100 days after
             discontinuation of study treatment and use appropriate barrier contraception or true
             abstinence

         11. Must not be receiving any other investigational product

        Exclusion Criteria:

        Patient -

          1. Is pregnant or lactating

          2. Is known to be hypersensitive to any of the components of 9-ING-41 or to the
             excipients used in its formulation

          3. Has >10% blasts in peripheral blood or bone marrow biopsy

          4. Has had a myocardial infarction within 12 weeks of the first dose of 9-ING-41

          5. Has any medical and/or social condition which, in the opinion of the investigator or
             study medical coordinator would preclude study participation

          6. Is considered to be a member of a vulnerable population (for example, prisoners)

          7. Herbal preparations / medications are prohibited throughout the study. These herbal
             medications include, but are not limited to St. John's wort, Kava, ephedra (ma huang),
             Gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and Ginseng.
             Patients should stop using cannabinoids or herbal preparations/medications at least 7
             days prior to first dose of study treatment -